Arizona 2024 Regular Session

Arizona House Bill HB2105 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 PREFILED JAN 03 2024 REFERENCE TITLE: psilocybin research State of Arizona House of Representatives Fifty-sixth Legislature Second Regular Session 2024 HB 2105 Introduced by Representative Payne An Act amending Laws 2023, chapter 139, section 6; relating to psilocybin research. (TEXT OF BILL BEGINS ON NEXT PAGE)
22
33
44
55
66
77 PREFILED JAN 03 2024
88
99 REFERENCE TITLE: psilocybin research
1010 State of Arizona House of Representatives Fifty-sixth Legislature Second Regular Session 2024
1111 HB 2105
1212 Introduced by Representative Payne
1313
1414 REFERENCE TITLE: psilocybin research
1515
1616
1717
1818
1919
2020
2121
2222
2323
2424 State of Arizona
2525
2626 House of Representatives
2727
2828 Fifty-sixth Legislature
2929
3030 Second Regular Session
3131
3232 2024
3333
3434
3535
3636
3737
3838
3939
4040 HB 2105
4141
4242
4343
4444 Introduced by
4545
4646 Representative Payne
4747
4848
4949
5050
5151
5252
5353
5454
5555
5656
5757
5858
5959
6060
6161
6262
6363
6464 An Act
6565
6666
6767
6868 amending Laws 2023, chapter 139, section 6; relating to psilocybin research.
6969
7070
7171
7272
7373
7474 (TEXT OF BILL BEGINS ON NEXT PAGE)
7575
7676
7777
7878 Be it enacted by the Legislature of the State of Arizona: Section 1. Laws 2023, chapter 139, section 6 is amended to read: Sec. 6. Department of health services; psilocybin research grants; advisory council; delayed repeal; definitions A. The director shall provide from monies appropriated competitive research grants for whole mushroom psilocybin phase one, phase two and phase three clinical trials that are capable of being approved by the United States food and drug administration to evaluate the effects of whole mushroom psilocybin on treating any of the following: 1. Post-traumatic stress disorder. 2. Symptoms associated with long COVID-19. 3. Depression. 4. Anxiety disorders. 5. Symptoms associated with end-of-life distress. 6. Obsessive compulsive disorder. 7. Substance abuse and addiction disorders. 8. Eating disorders. 9. Chronic pain. 10. Inflammatory disorders. 11. Autoimmune disorders. 12. Seizure disorders. 13. Other degenerative disorders. B. The department shall announce the opening of the application process at least thirty days before applications are available and allow at least thirty days for applicants to complete their submission. An applicant may apply for a research grant for only the clinical trial phase for which the applicant is initiating. Subject to available legislative appropriations, the research grants shall be awarded not later than February 1 each year. C. Clinical trials that are funded pursuant to this section shall prioritize: 1. Using whole mushroom psilocybin cultivated under a schedule I license issued by the United States drug enforcement administration. 2. Using veterans, first responders, frontline health care workers and persons from underserved communities as the research subjects. D. The department may not use more than two percent of the monies appropriated for psilocybin research grants each fiscal year for administrative purposes. E. Notwithstanding title 13, chapter 34, Arizona Revised Statutes, a person who receives a grant for a whole mushroom psilocybin clinical trial pursuant to this section and any of the person's employees working on the clinical trial may not be charged with or prosecuted for possession of psilocybin when the person is working on the clinical trial. F. The psilocybin research advisory council is established in the department consisting of the director or the director's designee who is employed by the department and the following members appointed by the director: 1. One member who has a federal license to study psychedelics and who is a physician licensed pursuant to title 32, chapter 13 or 17, Arizona Revised Statutes, and who has experience conducting clinical research involving the use of a schedule I controlled substance. 2. One member who is a military veteran. 3. One member who is a law enforcement officer in this state. 4. One member who is a professor or researcher from a university under the jurisdiction of the Arizona board of regents and who specializes in clinical research or psychedelic studies. G. The director shall serve as chairperson of the advisory council. H. Advisory council members are eligible to receive reimbursement of expenses pursuant to title 38, chapter 4, article 2, Arizona Revised Statutes. I. A member of the advisory council may not apply for a research grant under this section. I. j. The advisory council shall: 1. Establish criteria for the clinical trials that qualify to receive research grants. 2. Oversee the application process and review applications for the clinical trial research grants to assist the director in selecting the most credible clinical trials to award the research grants. 3. Ensure that all advisory council meetings are open to the public and allow for public testimony. 4. On or before June 1 of each year, make recommendations to the governor, the speaker of the house of representatives, the president of the senate and the department on psychedelic-assisted therapy based on current federal and state research policy. J. k. This section is repealed from and after June 30, 2026. K. l. For the purposes of this section: 1. "Advisory council" means the psilocybin research advisory council. 2. "Department" means the department of health services. 3. "Director" means the director of the department of health services. Sec. 2. Psilocybin research monies; exemption The amount appropriated for the psilocybin research line item in fiscal year 2023-2024 pursuant to Laws 2023, chapter 133, section 44 is exempt from the provisions of section 35-190, Arizona Revised Statutes, relating to lapsing of appropriations, until July 1, 2026. Sec. 3. Emergency This act is an emergency measure that is necessary to preserve the public peace, health or safety and is operative immediately as provided by law.
7979
8080 Be it enacted by the Legislature of the State of Arizona:
8181
8282 Section 1. Laws 2023, chapter 139, section 6 is amended to read:
8383
8484 Sec. 6. Department of health services; psilocybin research grants; advisory council; delayed repeal; definitions
8585
8686 A. The director shall provide from monies appropriated competitive research grants for whole mushroom psilocybin phase one, phase two and phase three clinical trials that are capable of being approved by the United States food and drug administration to evaluate the effects of whole mushroom psilocybin on treating any of the following:
8787
8888 1. Post-traumatic stress disorder.
8989
9090 2. Symptoms associated with long COVID-19.
9191
9292 3. Depression.
9393
9494 4. Anxiety disorders.
9595
9696 5. Symptoms associated with end-of-life distress.
9797
9898 6. Obsessive compulsive disorder.
9999
100100 7. Substance abuse and addiction disorders.
101101
102102 8. Eating disorders.
103103
104104 9. Chronic pain.
105105
106106 10. Inflammatory disorders.
107107
108108 11. Autoimmune disorders.
109109
110110 12. Seizure disorders.
111111
112112 13. Other degenerative disorders.
113113
114114 B. The department shall announce the opening of the application process at least thirty days before applications are available and allow at least thirty days for applicants to complete their submission. An applicant may apply for a research grant for only the clinical trial phase for which the applicant is initiating. Subject to available legislative appropriations, the research grants shall be awarded not later than February 1 each year.
115115
116116 C. Clinical trials that are funded pursuant to this section shall prioritize:
117117
118118 1. Using whole mushroom psilocybin cultivated under a schedule I license issued by the United States drug enforcement administration.
119119
120120 2. Using veterans, first responders, frontline health care workers and persons from underserved communities as the research subjects.
121121
122122 D. The department may not use more than two percent of the monies appropriated for psilocybin research grants each fiscal year for administrative purposes.
123123
124124 E. Notwithstanding title 13, chapter 34, Arizona Revised Statutes, a person who receives a grant for a whole mushroom psilocybin clinical trial pursuant to this section and any of the person's employees working on the clinical trial may not be charged with or prosecuted for possession of psilocybin when the person is working on the clinical trial.
125125
126126 F. The psilocybin research advisory council is established in the department consisting of the director or the director's designee who is employed by the department and the following members appointed by the director:
127127
128128 1. One member who has a federal license to study psychedelics and who is a physician licensed pursuant to title 32, chapter 13 or 17, Arizona Revised Statutes, and who has experience conducting clinical research involving the use of a schedule I controlled substance.
129129
130130 2. One member who is a military veteran.
131131
132132 3. One member who is a law enforcement officer in this state.
133133
134134 4. One member who is a professor or researcher from a university under the jurisdiction of the Arizona board of regents and who specializes in clinical research or psychedelic studies.
135135
136136 G. The director shall serve as chairperson of the advisory council.
137137
138138 H. Advisory council members are eligible to receive reimbursement of expenses pursuant to title 38, chapter 4, article 2, Arizona Revised Statutes.
139139
140140 I. A member of the advisory council may not apply for a research grant under this section.
141141
142142 I. j. The advisory council shall:
143143
144144 1. Establish criteria for the clinical trials that qualify to receive research grants.
145145
146146 2. Oversee the application process and review applications for the clinical trial research grants to assist the director in selecting the most credible clinical trials to award the research grants.
147147
148148 3. Ensure that all advisory council meetings are open to the public and allow for public testimony.
149149
150150 4. On or before June 1 of each year, make recommendations to the governor, the speaker of the house of representatives, the president of the senate and the department on psychedelic-assisted therapy based on current federal and state research policy.
151151
152152 J. k. This section is repealed from and after June 30, 2026.
153153
154154 K. l. For the purposes of this section:
155155
156156 1. "Advisory council" means the psilocybin research advisory council.
157157
158158 2. "Department" means the department of health services.
159159
160160 3. "Director" means the director of the department of health services.
161161
162162 Sec. 2. Psilocybin research monies; exemption
163163
164164 The amount appropriated for the psilocybin research line item in fiscal year 2023-2024 pursuant to Laws 2023, chapter 133, section 44 is exempt from the provisions of section 35-190, Arizona Revised Statutes, relating to lapsing of appropriations, until July 1, 2026.
165165
166166 Sec. 3. Emergency
167167
168168 This act is an emergency measure that is necessary to preserve the public peace, health or safety and is operative immediately as provided by law.